• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Indevus To Pay $120M For Valera In Specialty Buyout

Dec. 13, 2006
By Aaron Lorenzo

Investors Dump Nuvelo On Alfimeprase's Phase III Data

Dec. 12, 2006
By Aaron Lorenzo
Bad news for Nuvelo Inc.: Its partnered thrombolytic drug alfimeprase failed two Phase III studies, one in acute peripheral arterial occlusion (PAO) and the other in catheter occlusion (CO). (BioWorld Today)
Read More

Investors Dump Nuvelo On Alfimeprase's Phase III Data

Dec. 12, 2006
By Aaron Lorenzo
Bad news for Nuvelo Inc.: Its partnered thrombolytic drug alfimeprase failed two Phase III studies, one in acute peripheral arterial occlusion (PAO) and the other in catheter occlusion (CO). (BioWorld Today)
Read More

Theravance Submits NDA For Antibiotic Telavancin

Dec. 11, 2006
By Aaron Lorenzo

Senate Finally OKs Von Eschenbach As FDA Head

Dec. 11, 2006
By Aaron Lorenzo

Theravance Submits NDA For Antibiotic Telavancin

Dec. 11, 2006
By Aaron Lorenzo

Senate Finally OKs Von Eschenbach As FDA Head

Dec. 11, 2006
By Aaron Lorenzo

Senate expected to approve von Eschenbach as FDA head

Dec. 8, 2006
By Aaron Lorenzo

Vanda's Positive Phase III Data In Schizophrenia Boost Shares

Dec. 8, 2006
By Aaron Lorenzo
Vanda Pharmaceuticals Inc.'s positive Phase III results on the investigational schizophrenia drug iloperidone were well received by every measure, with the company's stock value soaring 68.7 percent Thursday, fueled by both the data and buyout rumors. (BioWorld Today)
Read More

Vanda's Positive Phase III Data In Schizophrenia Boost Shares

Dec. 8, 2006
By Aaron Lorenzo
Vanda Pharmaceuticals Inc.'s positive Phase III results on the investigational schizophrenia drug iloperidone were well received by every measure, with the company's stock value soaring 68.7 percent Thursday, fueled by both the data and buyout rumors. (BioWorld Today)
Read More
Previous 1 2 … 21 22 23 24 25 26 27 28 29 … 237 238 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 22, 2025.
  • Brain with handshake and cityscape

    Vigil takeover brings TREM2 Alzheimer’s prospect to Sanofi

    BioWorld
    Sanofi SA made good on its plan to bear down on M&A by agreeing to buy Vigil Neuroscience Inc. for $8 per share (NASDAQ:VIGL). Included in the transaction is a...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe